Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 2/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003682 | 0.93 | LOXL2 (0.38) | LOXL2KDM4ESMN1; SMN2RPS6KA3LATS1 | |
| SCHEMBL25150545 | 0.88 | TDP1 (0.38) | LOXL2KDM4ESMN1; SMN2RPS6KA3LATS1 | |
| SCHEMBL23869499 | 0.86 | TDP1 (0.37) | LOXL2RPS6KA3LATS1LATS2LMNA | |
| SCHEMBL26304408 | 0.85 | KDM4E (0.38) | LOXL2KDM4ESMN1; SMN2RPS6KA3LATS1 | |
| SCHEMBL10264269 | 0.85 | LOXL2 (0.42) | LOXL2RPS6KA3LATS1LATS2 | |
| SCHEMBL21783997 | 0.84 | RPS6KA3 (0.40) | LOXL2KDM4ESMN1; SMN2RPS6KA3LATS1 | |
| SCHEMBL23219779 | 0.80 | NR1I2 (0.38) | LOXL2RPS6KA3LATS1LATS2LMNA | |
| SCHEMBL18469769 | 0.79 | KDM4E (0.37) | LOXL2KDM4ESMN1; SMN2RPS6KA3CYP11B1 | |
| SCHEMBL24690502 | 0.77 | TDP1 (0.35) | LOXL2KDM4ESMN1; SMN2LMNATDP1 | |
| SCHEMBL20940108 | 0.76 | RPS6KA3 (0.41) | LOXL2SMN1; SMN2RPS6KA3LATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | LOXL2 4506/4885KDM4E 2261/4885SMN1; SMN2 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.